ERBB2 and ductal breast carcinoma in situ: HER2-high invasive tumors were characterized by upregulation of signatures involving interferon response, EMT and cell cycle, whereas HER2-high DCIS tumors exhibited upregulation of numerous molecular pathways, including several involved in cell metabolism (Suppl.